Stem cell transplants are among the highest-risk procedures in modern medicine. Depending on the type of transplant, between 4% and 45% of patients die from complications unrelated to the disease they were being treated for. That said, the procedure is typically reserved for life-threatening conditions like leukemia or lymphoma where the potential benefit outweighs serious risk, and outcomes have improved substantially over the past two decades.
Understanding the specific dangers, and which ones apply to your situation, makes the risk picture much clearer.
Two Types of Transplant, Two Levels of Risk
The distinction that matters most is whether the stem cells come from your own body (autologous) or from a donor (allogeneic). Autologous transplants are significantly safer. Across multiple studies, the death rate from transplant-related complications ranges from about 4% to 12% for autologous procedures. For allogeneic transplants using donor cells, that range jumps to roughly 5% to 45%, depending on the patient population, the donor match, and the intensity of the treatment beforehand.
The reason for this gap is straightforward: when you receive someone else’s cells, your body can reject them or, more commonly, the donor cells can attack your body. That immune conflict doesn’t exist when you receive your own cells back.
What Makes Conditioning So Hard on the Body
Before any stem cell transplant, you undergo “conditioning,” which is high-dose chemotherapy, sometimes combined with radiation. The goal is to destroy your existing bone marrow and, in the case of cancer, any remaining malignant cells. This phase is one of the most physically punishing parts of the process.
The intense treatment damages more than just bone marrow. It can injure the lining of blood vessels throughout your body, triggering a cascade of problems. One well-known complication is sinusoidal obstruction syndrome (sometimes called veno-occlusive disease), where damaged blood vessels in the liver become blocked. In patients receiving reduced-intensity conditioning, this occurs in roughly 1.6% of cases by day 50 post-transplant, but it’s far more dangerous than its low incidence suggests. Patients who develop it have a 23% death rate within the first 100 days, compared to about 6% for those who don’t.
Conditioning can also trigger a process where tiny blood clots form throughout the body’s small blood vessels, damaging the kidneys, lungs, brain, and gut. Kidney failure and pulmonary hypertension are among the more serious consequences, and kidney involvement in particular carries a poor prognosis.
Graft-Versus-Host Disease
This is the signature danger of donor transplants. It happens when the donor’s immune cells recognize your tissues as foreign and mount an attack. Graft-versus-host disease (GVHD) can affect the skin, liver, gut, lungs, eyes, and joints.
The good news is that rates have dropped sharply. In the late 1970s, nearly half of allogeneic transplant patients developed moderate to severe acute GVHD. By recent periods, that figure has fallen to about 16% for moderate-to-severe cases and just 4% for the most severe forms. Better donor matching, improved preventive medications, and refined conditioning regimens all contributed to this decline.
Severity matters enormously. Mild GVHD carries less than a 10% transplant-related death rate. The most severe form pushes that figure above 50%. Among patients who develop moderate or severe acute GVHD, the leading causes of death are the disease itself (17%), infections (19%), and chronic GVHD that persists long-term (9%).
Chronic GVHD, which develops months after transplant and can last years, brings its own set of problems. It has been linked to higher rates of diabetes, kidney dysfunction, bone deterioration, cataracts, and infertility. Patients with severe chronic GVHD, or disease affecting both the skin and internal organs, face roughly double the risk of developing these long-term complications.
Infection Risk During Recovery
For weeks to months after transplant, your immune system is essentially absent. This creates a predictable timeline of vulnerability. During the first month, bacterial and fungal infections are the primary threat, often from drug-resistant hospital-acquired organisms. Your body simply has no white blood cells to fight them off.
Between months one and six, the immunosuppressive medications needed to prevent GVHD open the door to opportunistic infections: viruses that were dormant in your body (like hepatitis B or cytomegalovirus) can reactivate, and fungal infections from common environmental sources become a real threat. This is generally the highest-risk window for opportunistic infections.
After six months, most patients are on lower doses of immunosuppression and the risks shift toward more ordinary community infections, including seasonal respiratory viruses and urinary tract infections. Preventive medications are typically stopped between 6 and 12 months, though transplant recipients remain somewhat more susceptible to common infections indefinitely.
Engraftment Failure
For the transplant to work, the new stem cells must take hold in your bone marrow and begin producing blood cells, a process called engraftment. When this fails, the consequences are severe. Data from cord blood transplants (which have higher failure rates than other donor sources) show that 75% of patients who hadn’t engrafted by day 28 died.
Overall engraftment rates vary by stem cell source. Cord blood transplants achieve engraftment in about 81% of cases, with roughly half engrafting by day 28 and the rest taking a few additional weeks. Transplants from matched adult donors generally have higher engraftment rates. When engraftment fails, a second transplant can be attempted. In one study, re-transplantation led to engraftment in 88% of cases, though it required a median of 53 additional days.
How Doctors Estimate Your Personal Risk
Not everyone faces the same level of danger. Transplant centers use a scoring system called the Hematopoietic Cell Transplant Comorbidity Index, which evaluates 17 pre-existing health conditions to predict how likely you are to survive. The results are striking in how much risk varies from person to person.
Patients with a score of zero (no significant comorbidities) have a two-year survival rate of about 83%. Those with scores of 1 to 2 are similar at 80%. But at scores of 3 to 4, survival drops to 74%, and patients scoring 5 or higher see two-year survival fall to just 56%. A score of 5 or above more than doubles the risk of death compared to a score of zero. Your age, organ function, fitness level, and the specific disease being treated all feed into the overall risk calculation.
Survival in Older Adults
Age is one of the strongest predictors of transplant outcomes. A recent meta-analysis of patients aged 70 and older who received allogeneic transplants found a median overall survival of about 15 months. Survival rates were 72% at six months, 55% at one year, 42% at two years, and 35% at three years. These numbers reflect the reality that older patients tolerate conditioning less well and are more likely to have comorbidities that compound risk.
For younger, healthier patients, outcomes are considerably better. The same procedure that carries 35% three-year survival in patients over 70 can achieve substantially higher survival rates in patients under 50 with fewer health problems.
Weighing the Danger Against the Disease
The risks of stem cell transplant are real and significant, but they exist in context. This procedure is almost never a first-line treatment. It’s offered when the disease itself poses a high probability of death, and when other treatments have failed or are unlikely to achieve long-term remission. For aggressive leukemias, certain lymphomas, and some bone marrow failure syndromes, transplant remains the only option with curative potential.
Autologous transplants for conditions like multiple myeloma carry single-digit mortality rates from the procedure itself, which is comparable to some major surgeries. Allogeneic transplants for high-risk blood cancers carry higher procedural mortality, but they also offer something chemotherapy alone often cannot: a new immune system capable of recognizing and destroying cancer cells long-term. That immune effect, called graft-versus-tumor, is part of why doctors accept the higher risk profile of donor transplants for certain diseases.